is a newly FDA-approved, first-in-class non-opioid oral medication (active ingredient: suzetrigine) developed by Vertex Pharmaceuticals to treat moderate to severe acute pain in adults.
It is the first new class of pain medicine approved for acute pain in over 20 years ⭐[1][4][6][9].
In summary, Journavx’s approval is viewed as a significant leap for acute pain management, providing an effective, non-addictive option and signaling progress in the effort to address the opioid crisis.
However, its high cost, moderate effectiveness compared to opioids, and still-limited diversity of clinical trial data are important considerations as it enters the market [1][2][4][5].